Optimizing Marketed Drugs™
Side Effect Fly
Tosk's patented Side Effect Fly technology uses Drosophila as a model to screen compounds for their potential to reduce or eliminate the adverse effects of existing drugs. This technology enables Tosk to efficiently identify side-effect-reducing compounds that would be difficult and costly to discover using traditional methods.
Many drugs, particularly those used for cancer chemotherapy, have toxic side effects that limit their use and effectiveness. Furthermore, these side effects can adversely affect patients' quality of life to the point that the therapy may be considered worse than the disease itself. In some cases, side effects limit dosage and the duration of therapy. Drugs that reduce the adverse effects therapies used to treat life-threatening diseases would be welcomed by the global medical community.
Genetically Modified Fly
Tosk has also developed proprietary technology to insert human genes into Drosophila to create drug screening platforms. The genetically modified flies are used to test compounds for their potential to block the action of disease-causing cancer genes.
The first application of Tosk's Genetically Modified Fly technology targets the human kRAS oncogene. A mutated kRAS gene is found in many types of cancers, including 90% of pancreatic cancer, 45% of colon cancer, and 35% of lung cancer. This gene is known to promote tumor growth. The gene may also limit the effectiveness of certain cancer drugs known as epidermal growth factor receptor (EGF-R) inhibitors. Tosk has successfully developed a kRAS fly and is deploying it to discover kRAS-blocking drugs.